Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations
出版年份 2018 全文链接
标题
Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations
作者
关键词
-
出版物
PROSTATE CANCER AND PROSTATIC DISEASES
Volume -, Issue -, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-08-21
DOI
10.1038/s41391-018-0079-0
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy
- (2018) Juan Morote et al. Clinical Genitourinary Cancer
- Testosterone Suppression with Luteinizing Hormone-Releasing Hormone (LHRH) Agonists in Patients Receiving Radiotherapy for Prostate Cancer
- (2018) Derek Wilke et al. PHARMACOTHERAPY
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
- (2017) Nicolas Mottet et al. EUROPEAN UROLOGY
- Darolutamide (ODM-201) for the treatment of prostate cancer
- (2017) Neal D. Shore EXPERT OPINION ON PHARMACOTHERAPY
- Molecular Dynamics Studies on the Enzalutamide Resistance Mechanisms Induced by Androgen Receptor Mutations
- (2017) Hongli Liu et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study
- (2017) Dong-Yi Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives
- (2017) Jieping Hu et al. TUMOR BIOLOGY
- The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy
- (2017) E. David Crawford et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and Metastasis
- (2017) Carsten Gründker et al. Frontiers in Endocrinology
- Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance
- (2017) Daniel Crona et al. Cancers
- Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer
- (2016) Jürgen Breul et al. ADVANCES IN THERAPY
- Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer
- (2016) Neal D. Shore et al. BJU INTERNATIONAL
- Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND)
- (2016) Claude Schulman et al. EUROPEAN UROLOGY
- Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
- (2016) Matthew R. Smith et al. EUROPEAN UROLOGY
- Behavior of chemiluminescent assays to measure serum testosterone during androgen deprivation therapy
- (2016) Juan Morote et al. INTERNATIONAL JOURNAL OF UROLOGY
- Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
- (2016) David F. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study
- (2016) Neal D Shore et al. LANCET ONCOLOGY
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- PSA and beyond: alternative prostate cancer biomarkers
- (2016) Sharanjot Saini CELLULAR ONCOLOGY
- Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer
- (2016) Dawn L. Hershman et al. JAMA Oncology
- Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl
- (2015) E David Crawford et al. Expert Opinion on Drug Metabolism & Toxicology
- Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males
- (2015) David B. MacLean et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT
- (2015) Laurence Klotz et al. JOURNAL OF CLINICAL ONCOLOGY
- Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade
- (2015) Shuhei Kamada et al. JOURNAL OF UROLOGY
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen receptor signaling in prostate cancer
- (2014) Zoran Culig et al. CANCER AND METASTASIS REVIEWS
- Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists
- (2014) Laurence Klotz et al. EUROPEAN UROLOGY
- Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study
- (2014) Mary-Ellen Taplin et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
- (2014) Karim Fizazi et al. LANCET ONCOLOGY
- NCCN guidelines for prostate cancer updated
- (2014) Nature Reviews Urology
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis
- (2014) Arie Carneiro et al. WORLD JOURNAL OF UROLOGY
- Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII
- (2014) Arto J. Salonen et al. Scandinavian Journal of Urology
- Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer
- (2014) Masis Isikbay et al. Hormones & Cancer
- Androgen-Targeted Therapy-Induced Epithelial Mesenchymal Plasticity and Neuroendocrine Transdifferentiation in Prostate Cancer: An Opportunity for Intervention
- (2014) Mannan Nouri et al. Frontiers in Oncology
- Molecular Pathways: Inhibiting Steroid Biosynthesis in Prostate Cancer
- (2013) R. Ferraldeschi et al. CLINICAL CANCER RESEARCH
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
- (2013) Axel Heidenreich et al. EUROPEAN UROLOGY
- A New Era of Testosterone and Prostate Cancer: From Physiology to Clinical Implications
- (2013) Mohit Khera et al. EUROPEAN UROLOGY
- Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist
- (2013) Peter C. Albertsen et al. EUROPEAN UROLOGY
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
- (2013) Axel Heidenreich et al. EUROPEAN UROLOGY
- Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
- (2013) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial
- (2013) Paul C. M. S. Verhagen et al. WORLD JOURNAL OF UROLOGY
- Goserelin versus leuprolide in the chemical castration of patients with prostate cancer
- (2012) Élcio Dias Silva et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Open, multi-center, phase IV study to assess the efficacy and tolerability of triptorelin in Taiwanese patients with advanced prostate cancer
- (2012) Chien-Chang Kao et al. Journal of the Chinese Medical Association
- Lower Testosterone Levels With Luteinizing Hormone-Releasing Hormone Agonist Therapy Than With Surgical Castration: New Insights Attained by Mass Spectrometry
- (2012) Tim M. van der Sluis et al. JOURNAL OF UROLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists
- (2012) N D Shore et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Wechsel des LHRH-Analogons beim progredienten kastrationsresistenten Prostatakarzinom
- (2012) A. Heidenreich et al. UROLOGE
- The Effect of Baseline Testosterone on the Efficacy of Degarelix and Leuprolide: Further Insights From A 12-Month, Comparative, Phase III Study in Prostate Cancer Patients
- (2012) Jan-Erik Damber et al. UROLOGY
- Testosterone in prostate cancer: the Bethesda consensus
- (2011) Bob Djavan et al. BJU INTERNATIONAL
- New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist
- (2011) Marc B. Garnick et al. BJU INTERNATIONAL
- Efficacy of a Second Line Luteinizing Hormone-Releasing Hormone Agonist After Advanced Prostate Cancer Biochemical Recurrence
- (2011) Nathan Lawrentschuk et al. JOURNAL OF UROLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer
- (2011) A Spitz et al. PROSTATE CANCER AND PROSTATIC DISEASES
- The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness
- (2009) Juan Morote et al. BJU INTERNATIONAL
- Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
- (2009) Massimo Perachino et al. BJU INTERNATIONAL
- Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk
- (2009) Juan Morote et al. BJU INTERNATIONAL
- Patient adherence and persistence with oral anticancer treatment
- (2009) K. Ruddy et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Triptorelin 6-Month Formulation in the Management of Patients with Locally Advanced and Metastatic Prostate Cancer
- (2009) Eija A. Lundström et al. CLINICAL DRUG INVESTIGATION
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
- (2008) Laurence Klotz et al. BJU INTERNATIONAL
- Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker—Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate Cancer
- (2008) Hendrik Van Poppel et al. EUROPEAN UROLOGY
- Androgen Suppression and Radiation vs Radiation Alone for Prostate Cancer
- (2008) Anthony V. D’Amico et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North America
- (2008) Marc Gittelman et al. JOURNAL OF UROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now